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Abstract
Background: The manipulation of dendritic cells (DCs) for cancer vaccination has not reached its full potential,
despite the revolution in cancer immunotherapy. DCs are fundamental for CD8+ T cell activation, which relies on
cross-presentation of exogenous antigen on MHC-I and can be fostered by immunogenic cancer cell death.
Translational and clinical research has focused on in vitro-generated monocyte-derived DCs, while the vaccination
efficacy of natural conventional type 1 DCs (cDC1s), which are associated with improved anti-tumor immunity and
specialize on antigen cross-presentation, remains unknown.
Methods: We isolated primary spleen mouse cDC1s and established a protocol for fast ex vivo activation and antigen-
loading with lysates of tumor cells that underwent immunogenic cell death by UV irradiation. Natural tumor
antigen-loaded cDC1s were transferred and their potential for induction of endogenous CD8+ and CD4+ T
cell responses in vivo, cancer prevention and therapy were assessed in three grafted cancer models. Further,
we tested the efficacy of natural cDC1 vaccination in combination and comparison with anti-PD-1 treatment
in two “wildtype” tumor models not expressing exogenous antigens.
Results: Herein, we reveal that primary mouse cDC1s ex vivo loaded with dead tumor cell-derived antigen
are activated and induce strong CD8+ T cell responses from the endogenous repertoire upon adoptive transfer in
vivo through tumor antigen cross-presentation. Notably, cDC1-based vaccines enhance tumor infiltration by cancer-
reactive CD8+ and CD4+ T cells and halt progression of engrafted cancer models, including tumors that are refractory
to anti-PD-1 treatment. Moreover, combined tumor antigen-loaded primary cDC1 and anti-PD-1 therapy had strong
synergistic effects in a PD-1 checkpoint inhibition susceptible cancer model.
Conclusions: This preclinical proof-of-principle study is first to support the therapeutic efficacy of cancer immunotherapy
with syngeneic dead tumor cell antigen-loaded mouse cDC1s, the equivalents of the human dendritic cell subset that
correlates with beneficial prognosis of cancer patients. Our data pave the way for translation of cDC1-based cancer
treatments into the clinic when isolation of natural human cDC1s becomes feasible.
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Background
Cytotoxic CD8+ T lymphocytes (CD8+ CTLs) are key
effector cells that recognize and eliminate tumor cells
and therefore preferential targets for improving cancer
immunotherapy [1]. However, cancer-reactive CD8+ T
cells can become dysfunctional or exhausted limiting
their efficacy [2]. Immune checkpoint inhibitors, such as
anti-PD-1 or anti-CTLA4, have achieved unprecedented
success in the treatment of various cancers by reinvigor-
ating exhausted CD8+ CTLs. Unfortunately, their clin-
ical benefits remain limited and it is crucial to find
additional strategies to increase basal anti-tumor CD8+
T cell immunity [3, 4].
Dendritic cell (DC) vaccines may elicit and improve
anti-cancer CD8+ T cell immunity [5, 6]. However, the
use of DCs for tumor immunotherapy has been limited
so far, being the only FDA-approved therapy the blood
antigen (Ag)-presenting cell-based vaccine Sipuleucel-T
for metastatic castration-resistant prostate cancer [7].
Currently, most clinical efforts focus on human blood
monocyte-derived DCs (moDCs) cultured for several
days with GM-CSF and IL-4, loaded with various Ags
and stimulated with proinflammatory adjuvants [6, 8–10].
Numerous clinical trials are ongoing that test the efficacy
of moDC-based vaccination against different types of
cancer as single agents or combination therapies. Combin-
ation of DC vaccination and immune checkpoint inhibi-
tors appears especially promising, as both target enhanced
mobilization and activity of anti-cancer CD8+ T cells
[5, 6, 11]. In general, adoptive transfer of ex vivo-treated
DCs to cancer patients demonstrated an excellent safety
profile, but the efficacy did not meet the expectations
yet [12].
The advance in understanding of distinct DC subset
functions calls for the development of next-generation
DC vaccines, by using primary DC subsets from patient
blood that excel in induction of anti-cancer CD8+ T cell
immunity [8, 10, 11, 13, 14]. Circulating human DC sub-
sets comprise two types of conventional (c) DCs, cDC1s
(BDCA3+ cDCs) and cDC2s (CD1c+ cDCs) as well as
plasmacytoid DCs (BDCA2+ BDCA4+ pDCs), which
specialize on different functions [15]. Both human pDCs
and cDC2s from blood have been used as basis for
next-generation DC vaccines [16, 17], which led to an on-
going phase III clinical trial (ClinicalTrials.gov identifier:
NCT02993315).
Human cDC1s (DNGR-1/CLEC9A+, XCR1+) and their
mouse equivalents (DNGR-1/Clec9a+, Xcr1+, also express-
ing CD8 in lymphoid organs) are strong inducers of CD8+
T cell responses due to their superior capacity for uptake of
dying or dead cell material and processing of cancer
cell-associated Ags for cross-presentation [18–22].
Moreover, cDC1s are the main cellular source of IL-12
[23], a fundamental cytokine for anti-cancer CD8+ CTL
activation [24]. Those functional traits support the notion
that cDC1s are the superior DC subset for induction of
anti-tumor immunity [25, 26]. Indeed, Batf3-dependent
cDC1s are needed to mount anti-tumor CD8+ T cell re-
sponses at baseline [25] or upon poly I:C therapy [27] and
are indispensable for efficacy of immune checkpoint
blockade [28, 29]. Moreover, cDC1s are critical for the
transport of intact tumor-Ag to lymph nodes (LNs) to elicit
anti-tumor T cell activation [29, 30] and the secretion of
CXCL9/10 by tumor-infiltrating cDC1s is crucial for the re-
cruitment of CD8+ T cells into tumors [31]. Moreover, a
variety of studies show that presence of cross-presenting
BDCA3+ cDC1s or their gene signatures in the tumor cor-
relates with enhanced T cell infiltration, improved progno-
sis and survival of cancer patients [26, 30, 32, 33].
Despite these evidences, natural cDC1s have not been
previously tested as a syngeneic vaccine in cancer ther-
apy. We herein demonstrate the feasibility and efficacy
of an anti-cancer treatment based on adoptive transfer
of the natural cross-presenting mouse cDC1 subset
loaded ex vivo with an autologous whole tumor cell lys-
ate (TCL) obtained after induction of immunogenic cell
death (ICD) by UV irradiation. The cDC1 vaccine in-
duces substantial anti-tumor CD8+ T cell responses
from the endogenous repertoire in vivo, that depend on
their cell-autonomous cross-presentation potential. Not-
ably, this treatment fosters tumor-reactive CD8+ and
CD4+ T cell presence in tumors and tumor-draining
LNs (tdLN), limiting tumor progression of three differ-
ent mouse cancer models, of which two do not express
exogenous or dominant Ags. TCL-loaded cDC1 admin-
istration profoundly improves anti-PD-1 therapy in an
immune checkpoint antibody sensitive model and, not-
ably, is also effective for treatment of tumors that are re-
fractory to anti-PD-1. Therefore, we provide valuable
pre-clinical information on the efficacy of therapeutic
cDC1-based anti-cancer vaccination for the development
of next-generation DC vaccines [8].
Methods
Mice
Mouse colonies were bred at the CNIC under specific
pathogen-free conditions. Wildtype mice were in C57BL/6
background and 6–10-weeks old females used for all
experiments. B6.C-H2-Kbm1 (B6.C-H2-Kbm1/ByJ or C57BL/
6H2Kbm1) mice were kindly provided by Caetano Reis e Sousa
(The Crick Institute, London, UK) and OT-I transgenic mice
(C57BL/6-Tg (TcraTcrb)1100Mjb/J) crossed with B6-SJL
(Ptprca Pepcb/BoyJ) mice expressing the CD45.1 allele were
both from The Jackson Laboratory (Bar Harbor, ME, USA).
Tissue dissociation for cell isolation
Spleen and inguinal lymph nodes (iLNs) were harvested
in R10 medium [RPMI Medium 1640 (Gibco®) with 10%
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heat-inactivated Fetal Bovine Serum (hi-FBS), 50 μM
β-Mercaptoethanol (both Sigma), 2 mM L-Glutamine,
100 U/mL Penicillin and Streptomycin (100 μg both
Lonza), 0.1 mM NEAA, 1 mM Sodium Pyruvate, 1 mM
HEPES (all from HyClone™)]. Spleen was digested for 10
min with 0.25 mg/ml Liberase TL (Roche) and 50 μg/ml
DNaseI (Sigma Aldrich). Tumors were minced and
incubated for 30 min in HBSS (Gibco®) with 0.5 mg/
ml Collagenase IV (Sigma) and 50 μg/ml DNAseI
shacking at 37 °C. Tissues were squeezed through a
70 μm cell strainer (Corning), re-filtered through a
40 μm cell strainer and spleen subjected for 5 min to
Red Blood Cell Lysis Buffer (Sigma).
Purification and adoptive transfer of CD8+ spleen DCs
For cDC1 expansion, 2.5 × 106 B16-Flt3L cells in 100 μl
PBS were inoculated subcutaneously into both flanks of
wildtype or C57BL/6H2Kbm1 mice and spleens harvested
9–11 days thereafter or naïve mice used. Spleen CD8+
cDC1 cells were isolated using the mouse CD8+
Dendritic Cell Isolation Kit (Order no. 130–091-169)
using MACS® columns and autoMACS™ Running Buffer
according to manufacturer’s instructions (Miltenyi Bio-
tec). In brief, spleen single cell suspensions were sub-
jected to negative selection that depletes T, B and NK
cells, followed by positive selection of CD8a DCs. Puri-
fied cDC1s were cultured in round-bottom 96-well
plates (Corning) at 2 × 105 cDC1s/200 μl R10 medium
for 1 h at 37 °C in 5% CO2 together with (as specified for
experiments): 20 μg/ml poly I:C LMW (InVivoGen),
20 μg/ml Hiltonol (kindly provided by Andres Salazar
from Oncovir), 20 μg/ml BO112 (Bioncotech Therapeu-
tics), 20 μg/ml endotoxin-free soluble OVA protein
(EndoGrade from Hyglos), and/or B16-OVA, B16/F10 or
MC38 TCL at a ratio of 1 DC to 2 tumor cells. cDC1s
were washed with R10 and, when incubated with TCL,
re-purified using MACS® columns. Cells were kept in
culture for 4 h for analysis of CD86 and MHC-II induc-
tion, immediately added to naive OT-I cells or 2–10 ×
105 cDC1s injected intravenously (100 μl PBS, Gibco®) or
intradermally (50 μl PBS) into mice. Anti-PD-1 (clone
RMP1–14 from BioXCell) was administered intraperito-
neal at 100 μg/mouse in 100 μl PBS.
OT-I CD8+ T cell assays
Total spleen CD8+ OT-I cells for in vivo assays were
purified from CD45.1 OT-I transgenic mice by negative
selection as follows: 30 min incubation of spleen single
cell suspensions with biotinylated antibodies (all BD Bio-
sciences) for anti-mouse CD16/CD32 (clone 2.4G2),
CD4 (clone GK1.5), B220 (clone RA3-6B2), CD11c
(clone HL3), CD11b (clone M1/70), Gr-1 (clone
RB6-8C5) and I-A/I-E (MHC-II, clone 2G9) at 4 °C
shaking, washing, 20 min incubation with Streptavidin
MicroBeads in autoMACS™ Running Buffer and mag-
netic separation using LD columns (all Miltenyi Biotec)
according to manufacturer’s instructions. For ex vivo
proliferation assay, naive CD8+ CD44- CD62L+ OT-I
cells were isolated by flow cytometric sorting using the
SY3200 Cell Sorter (Sony Biotechnology). Cells were
labeled with CellTrace™ Violet Cell Proliferation Kit
(Thermofisher, Molecular Probes) according to manufac-
turer’s instructions. 1-2 × 105 total labeled OT-I cells in
100 μl PBS were injected intravenously into mice. Naive
OT-I cells were cultured for 3 days with pre-treated
cDC1s in R10 medium (1:1 ratio) in round-bottom
96-well plates at 37 °C in 5% CO2 followed by flow
cytometric analysis of proliferation by dilution of the
CellTrace™ Violet dye.
Fluorescent staining, flow cytometry and cell sorting
Single cell suspensions of cDC1s, spleen, iLN and tu-
mors or cultured OT-I cells were incubated for 20 min
at 4 °C in PBS with 2% hi-FBS and 0.5 mM EDTA
(Sigma) with FcR block anti-mouse CD16/CD32 (2.4G2,
Tonbo Biosciences) and a mix of the following
fluorochrome-conjugated antibodies: anti-mouse CD45.1
(clone A20), CD44 (clone IM7), SIRPα (clone P84) and
CD62L (MEL-14) from eBioscience™, CD11c (clone
HL3), CD11b (clone M1/70), and I-A/I-E (MHC-II,
clone 2G9) from BD Biosciences, CD3 (clone 17A2),
CD86 (clone GL-1) and PD-1 (clone J43.1) from Tonbo
Biosciences, CD8 (clone 53–6.7) from BioLegend, XCR1
(clone REA707), CD205 (clone NLDC-145), Clec9A
(clone 7H11) and CD24 (clone M1/69) from Miltenyi
Biotec. When indicated, cells were beforehand incubated
with Allophycocyanin-conjugated OVA H-2Kb (257-
SIINFEKL-264) dextramer (Immunodex, catalogue num-
ber JD2163) or a mix of allophycocyanin-conjugated
OVA-specific MHC-II tetramers (I-A(b) 329-AAHA
EINEA-337, I-A(b) 328-HAAHAEINEA-337 and I-A(b)
325-QAVHAAHAEIN-325; all from the NIH Tetramer
Facility at Emory University) for 20 min at room
temperature. Hoechst 332558 (Sigma) or SYTOX Green
(Thermofisher) was used to exclude dead cells. The
LSRFortessa cell analyzer running FACSDiva software
(BD Biosciences) and FlowJo Version 10 or FCS Express
6 Plus software was used to record and analyze data.
Tumor cell culture, inoculation, in vivo analysis and
HMGB1 ELISA
B16/F10 (a kind gift from I. Malanchi, The Crick Institute,
London, UK), B16-OVA (a kind gift from L. Chen, Yale
University, New Haven, CT), MC38 (purchased from the
ATCC) [28] and B16-Flt3L cells (kindly provided by G.
Dranoff, Harvard University, Boston, MA) [34] were cul-
tured at 37 °C in 5% CO2 in R10 medium. The B16-OVA
cell line expresses a truncated and non-secreted OVA
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protein without the signal peptide as a fusion protein with
EGFP-C1, as previously described for mouse embryonic fi-
broblasts [35]. All cell lines were tested for absence of
mycoplasma using the MycoAlert PLUS Mycoplasma De-
tection Kit (Lonza) according to manufacturer’s instruc-
tions. Tumor cells were detached (5mM EDTA/PBS)
before reaching confluence and 1 × 106 B16-OVA or 0.5 ×
106 B16/F10 cells inoculated intradermal or 0.5 × 106
MC38 cells inoculated subcutaneous in 50 μl PBS into the
shaved right flank of wildtype mice. Tumor size was mea-
sured three times weekly using a digital caliper (Ratio),
calculated as the product of orthogonal diameters and is
displayed in mm2. Tumor-bearing mice were monitored
daily and sacrificed to determine the survival curve when
signs of adverse effects (pain, apathy, dehydration, necrotic
tumor) were observed or the humane endpoint (tumor
size diameter 1.7 cm) reached. Pictures were taken at indi-
cated time points using a digital camera. For HMGB1
ELISA, 0.5 × 106 cancer cells were UV-irradiated or
treated with doxorubicin (25μM), brefeldin A (50μM)
or mitomycin C (30μM, all from Sigma) and cultured
in 1 ml R10 for 18 h, supernatant harvested and solid
components removed by centrifugation. HMGB1 was
measured using the HMGB1 ELISA (IBL international
GmbH) following manufacturer’s instructions.
Tumor cell lysate preparation
B16-OVA, B16/F10 or MC38 tumor cells were adjusted
to 4 × 106 cells/ml in R10 medium, 1.5 ml per well plated
in 6-well plates (Corning) and treated with 300mJ/cm2
UV irradiation using a Stratalinker UV Crosslinker 1800
(Stratagene). Cells were cultured for 16-24 h at 37 °C in
5% CO2, subjected to 3 freeze (− 80 °C) / thaw (37 °C)
cycles of minimum 30min each and passed through a
40 μm cell strainer before addition to cDC1s at a ratio of
1 DC to 2 tumor cells. B16-OVA TCL was twice washed
with R10 and centrifuged at full-speed to remove soluble
components and obtain “washed B16-OVA TCL”.
Spleen, tdLN and tumor re-stimulation
For intracellular IFNγ staining, single cell suspensions
were ex vivo re-stimulated with 2 μM OVA257–264 pep-
tide (SIINFEKL, GenScript), OVA323–339 peptide (ISQAV
HAAHAEINEAGR, GenScript)-loaded or B16-OVA
TCL-loaded antigen-presenting cells (APCs) for 2 h in
R10 at 37 °C in 5% CO2 followed by 5 μg/mL Brefeldin
A (Sigma Aldrich) treatment for 4 h. Cells were labeled
with indicated surface-staining antibodies, fixed with 4%
PFA (Thermofisher), permeabilized with 1% Bovine
Serum Albumin, 0.1% Saponin, 0.02% Sodium Azide (all
Sigma) in PBS and stained with Allophycocyanin-conju-
gated anti-mouse IFNγ antibody (clone XMG1.2,
eBioscience™). APCs were generated from bone marrow
cells, harvested by flushing the tibia and femur and a red
blood cell lysis. Then, bone marrow was cultured in R10
with 20 ng/ml murine GM-CSF (Peprotech) for 7 days;
floating cells were harvested and incubated with either
5 μM OVA323–339 peptide or B16-OVA TCL for 8 h
followed by addition of 100 ng/ml LPS-EK (InvivoGen)
for another 12 h.
RNA isolation and quantitative PCR
Total RNA was extracted with the RNeasy Micro Kit
(Qiagen) and reverse transcribed using the High Cap-
acity cDNA Reverse Transcription Kit with random hex-
amers (Applied Biosystems®) following manufacturer’s
instructions. Quantitative PCR was performed using the
GoTaq® qPCR Master Mix (Promega) in a 7900HT Fast
Real-Time PCR System (Applied Byosystem®). 2-ΔCt
mRNA expression values of mouse Ifnb1, Il12b, CD40


















Data analyses employed GraphPad Prism version 7.0c.
Data are presented as mean ± standard error of the
mean, individual values, staircase graph with ticks, ‘scat-
ter plot with box & whiskers’ and/or ‘scatter plot with
column bar’ graph and were analyzed using Two-tailed
Student’s t-test (Paired or unpaired according to experi-
mental setting), One-way ANOVA and Tukey post hoc
test, Mantel-Cox test and Two-way ANOVA. All
experiments were repeated at least twice and either rep-
resentative experiments or pooled data from several ex-
periments are shown as indicated in the figure legends.
Mice were allocated randomly in different experimental
groups, but no blinding or randomization strategy was
used. No animals were excluded from analysis, unless
they had wounds from fighting/over-grooming. All n
values represent biological replicates (different mice, pri-
mary cell preparations or in vitro experiments). Differ-
ences were considered significant when P < 0.05 and are
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indicated as ns, not significant, *P < 0.05, **P < 0.01,
***P < 0.001.
Results
Adoptive transfer of antigen and adjuvant-treated natural
mouse cDC1s promotes CD8+ T cell immunity
Comparative transcriptional and functional analyses
have established that mouse spleen CD8α+ cDC1s are
the equivalents of human circulating BDCA3+ cDC1s
[18–21]. Therefore, we used naturally occurring mouse
spleen CD8α+ cDC1 in order to test the suitability of
cDC1s as basis for effective cancer therapy. Human
anti-cancer DC vaccines are based on autologous DCs
obtained from the cancer patient [36]. To reproduce this
situation in our pre-clinical setting while expanding
cDC1s, mice were grafted with B16 melanomas that
secrete FMS-like tyrosine kinase 3 ligand (FLT3L)
(B16-FLT3L) [34]. CD11c+MHC-II+ CD8α+ cDC1s iso-
lated from the spleen of both steady-state and
B16-FLT3L tumor-bearing donor mice showed similar
patterns of surface markers, including high XCR1,
CD205, Clec9A and CD24, as well as no/low CD11b and
SIRPα expression (Additional file 1: Figure S1), suggest-
ing no major phenotypic alteration of cDC1s in
B16-FLT3L tumor-bearing mice.
To address the efficacy of naturally occurring cDC1s
for the induction of CD8+ T cell immunity upon transfer
in vivo, we treated cDC1s ex vivo with soluble Ovalbu-
min (OVA) as Ag and poly I:C, a synthetic double-
stranded RNA adjuvant that binds Toll-like receptor
(TLR) 3, which is selectively expressed by mouse and
human cDC1s and promotes their activation and func-
tion [20, 27]. Indeed, poly I:C treatment ex vivo rapidly
activated natural mouse cDC1s, inducing transcription
of cytokines and surface receptors involved in CD8+ T
cell priming (Fig. 1a). Natural cDC1s were then intra-
venously (IV) injected into syngeneic recipient mice that
were previously adoptively transferred with OT-I
OVA-specific CD8+ T cells (Fig. 1b). Adoptive transfer
of natural cDC1s shortly exposed to OVA and poly I:C
ex vivo led to increased OT-I proliferation, frequencies
in CD8+ T cells and total numbers, as well as aug-
mented IFNγ producing OT-I cells after specific
MHC-class I OVA257–264 peptide re-stimulation, as com-
pared with mice transferred with cDC1s pre-treated only
with OVA or poly I:C (Fig. 1c-f ). Hence, natural spleen
cDC1s treated ex vivo with Ag and adjuvant for just 1 h
strongly activate CD8+ T cells in vivo in an adjuvant and
Ag-dependent fashion.
Tumor cell lysate-loaded cDC1s generate optimal CD8+ T
cell activation in vivo
Most Ag preparations and delivery regimes for induc-
tion of anti-tumor immunity have been optimized for
in vitro-generated moDCs and may be not equally
suitable for natural DC subsets with specific intrinsic
functional properties. Utilization of a variety of differ-
ent tumor-associated Ags is likely to enhance the effi-
cacy of DCs to mount a general anti-cancer immune
response and thereby limits the escape of individual
tumor-Ag variant loss. Enticingly, ICD of tumor cells
induced by methods such as UV irradiation induces
strong DC-mediated immunity to dead-cell associated
Ags [37, 38]. Therefore, we prepared syngeneic TCL
of total mouse cancer cells by UV irradiation,
followed by culture o/n to allow secondary necrosis
and 3 freeze/thaw cycles to ensure cell death (Additional
file 1: Figure S2a). UV irradiation induced release of
high-mobility group box protein 1 (HMGB1), a hallmark
of ICD, by OVA-expressing B16 melanoma cells
(B16-OVA) [28], even higher than the strong ICD-inducer
doxorubicin, whereas the non-ICD inducers mitomycin C
and brefeldin A [38, 39] had no effect (Fig. 2a).
ICD-mediated HMGB1 release results in DC activation
and cross presentation [40, 41]. In line, natural spleen
cDC1s treated ex vivo with B16-OVA TCL upregulated
CD86 and MHC-II expression, which was dependent on
soluble factors as washed TCL failed to do so (Fig. 2b and
Additional file 1: Figure S2b). Addition of the potent
stimulant poly I:C during TCL treatment further amplified
their maturation, while CD86 levels remained slightly
higher in TCL-treated cDC1s compared to controls
(Fig. 2b and Additional file 1: Figure S2b). To deter-
mine optimal cDC1 activation, cDC1s were exposed
to B16-OVA TCL in the presence of poly I:C (from
InvivoGen), Hiltonol® (poly ICLC from Oncovir Inc.,
in clinical use) or BO-112 (a synthetic dsRNA com-
plex targeting cytosolic helicases MDA5 and RIG-I as
well as TLR3, in clinical trials: ClinicalTrials.gov iden-
tifier: NCT02828098). B16-OVA TCL-loaded and poly
I:C-treated cDC1s showed the strongest potential to
induce naive OT-I CD8+ T cell proliferation ex vivo,
while the clinical-grade poly I:C analogues BO-112
and Hiltonol® were less effective (Fig. 2c). Hence, we
focused on poly I:C as optimized adjuvant for primary
mouse spleen cDC1s.
Next, we tested the efficiency of in vivo administration of
cDC1s treated with B16-OVA TCL and poly I:C in mice
adoptively transferred with OT-I CD8+ T cells. Notably,
cDC1s treated with B16-OVA TCL and poly I:C induced
increased total OT-I number and frequency as well as aug-
mented IFNγ production upon OVA257–264 re-stimulation
of splenocytes compared with poly I:C + soluble OVA-
treated cDC1s and additional control treatments without
cDC1s or without Ag (Fig. 2d and Additional file 1:
Figure S2c & d). This observation pointed towards the
efficacy of UV irradiation-induced TCL as an optimal Ag
source for natural cDC1s fostering their activation.
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Once established an optimal adjuvant-Ag combination,
we tested administration of TCL-loaded cDC1s via intra-
dermal (ID) or IV injection in OT-I transferred mice. IV
injection of B16-OVA TCL-loaded cDC1s induced
strong OT-I T cell responses in the spleen but minor ef-
fects in the iLN, while ID administration induced strong
OT-I expansion both in the spleen and the draining iLN
(Fig. 2e). This result suggested ID administration as the
optimal injection route for TCL-loaded cDC1s for treat-
ment of tumors growing in the skin such as melanoma.
Tumor Ag-loaded cDC1s cross-prime endogenous CD8+ T
cells
We aimed to determine the potency of TCL-loaded
cDC1s to stimulate effector responses from the endogen-
ous repertoire of CD8+ T cells (Fig. 3a). Following ID
administration of B16-OVA TCL-loaded cDC1s to naive
mice, we found increased cellularity in the iLN, including
augmented numbers of CD8+ T cells and higher fre-
quency and numbers of activated OVA-specific
(H-2Kb-OVA257–264+) CD8+ T cells (Fig. 3b & c and
Additional file 1: Figure S3a). These data show that trans-
ferred TCL-loaded cDC1s prime endogenous CD8+ T cells.
Of note, the whole TCL contains other Ags in addition to
OVA, which would increase the total number of cDC1
vaccine-induced endogenous anti-tumor CD8+ Tcells.
Next, we evaluated if the observed induction of en-
dogenous CD8+ T cell responses in vivo was dependent
on cross-presentation on MHC-I of the ex vivo acquired
tumor-Ag by the transferred cDC1s. cDC1s were ob-
tained from B16-FLT3L tumor-grafted WT and C57BL/
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Fig. 1 Adoptive transfer of Ag and adjuvant-treated natural mouse cDC1s promotes CD8+ T cell immunity. a Quantitative PCR analyses of mRNA
levels of Ifnb1 (IFNβ protein), Il12b (IL12-p40 protein), CD40 and CCR7 relative to Actb (β-actin protein) of spleen cDC1s freshly isolated from B16-FLT3L
tumor-bearing mice and treated with 20 μg/ml poly I:C (InvivoGen) for 1 h ex vivo, n = 4 spleen cDC1 preparations. *P < 0.05 by Ratio paired Student’s
t test. Ct: Cycle threshold, −ΔCt = −(Ct [gene of interest] - Ct [Actb internal control gene]). b Schematic representation of experimental setup for data
shown in c-f. Spleen cDC1s from B16-FLT3L tumor-bearing mice were cultured with 20 μg/ml poly I:C and/or 20 μg/ml soluble OVA protein for 1 h,
washed and 2 × 105 cDC1s injected intravenously into CD45.2+ recipient mice that had been adoptively transferred with 1-2 × 105 CellTrace-Violet
(CV)-labelled CD45.1+ OT-I CD8+ T cells one-day prior. c Representative flow cytometric analysis of OT-I T cell proliferation via CV-dilution in the spleen
at day 5, gated on CD45.1+ CD8+ OT-I cells. d-f Flow cytometric quantification of d total OT-I cell number, e OT-I frequency in CD8+ cells and f
number of IFNγ-producing OT-I cells after re-stimulation with OVA257–264 peptide in the spleen at day 5 post-cDC1 injection. One representative
of 2 independent experiments (n = 3–4 mice/group/experiment) is shown. *P < 0.05, **P < 0.01 by Student’s t test






















































































































































































































































































































































































































































Fig. 2 TCL induces cDC1 activation and TCL-loaded cDC1s generate optimal CD8+ T cell activation in vivo. a HMGB1 content measured by ELISA
in supernatants of B16-OVA cells treated with indicated agents (n = 3–4). b Quantification (left) and representative histograms (right) of CD86
expression on untreated cDC1s (Untreat.), cDC1s treated either with B16-OVA tumor cell lysate (TCL) or washed B16-OVA TCL containing only
cellular components +/− 20 μg/ml poly I:C. After 1 h, cDC1s were washed and cultured for 4 h followed by flow cytometric analysis. Combined
data of 4 independent experiments. MFI, mean fluorescent intensity. c Spleen cDC1s were cultured with B16-OVA TCL, poly I:C, Hiltonol and/or
BO112 for 1 h, re-purified and plated with CellTrace Violet (CV)-labelled OT-I cells. Quantification (left) and representative histograms (right) of OT-I
cell proliferation 3 days after. Combined data of 3 independent experiments. d cDC1s were cultured for 1 h with poly I:C, soluble OVA protein
and/or B16-OVA TCL and 2 × 105 cDC1s were injected intravenously (IV) into CD45.2+ recipient mice that had received 1-2 × 105 CV-labelled
CD45.1+ OT-I CD8+ T cells one-day prior. Equally treated “leftover” B16-OVA TCL served as negative control (Additional file 1: Figure S2d). Total
OT-I cell number and number of IFNγ-producing OT-I cells after re-stimulation with OVA257–264 peptide was determined by flow cytometric
quantification in spleen 5 days later. One representative of 2 independent experiments with n = 3 mice/group/experiment. e cDC1s were cultured
for 1 h with poly I:C and B16-OVA TCL and 2 × 105 cDC1s were IV or intradermally (ID) injected into CD45.2+ recipient mice that had received 1-
2 × 105 CD45.1+ OT-I CD8+ T cells one-day prior. Equally treated “leftover” B16-OVA TCL served as negative control (Additional file 1: Figure S2d).
OT-I number and frequency was determined by flow cytometric quantification in spleen and draining lymph node (iLN) 5 days later. One
representative of 2 independent experiments with n = 4 mice/group/experiment. *P < 0.05, **P < 0.01, ***P < 0.001 by a & c-e one-way
ANOVA and Tukey post hoc test or b paired Student’s t test
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the H-2K MHC-I molecule preventing the presentation
of OVA257–264 peptide [42] (Fig. 3a). Adoptive transfer
(ID) of TCL-loaded poly I:C-treated cDC1s from
H-2Kbm1 mice led to similar induction of total cellularity
and amount of CD8+ T cells in the iLN compared with
WT cDC1s (Fig. 3d and Additional file 1: Figure S3b). In
contrast, transfer of cDC1s from H-2Kbm1 mice resulted
in reduced numbers and frequencies of activated CD44+
IFNγ-producing CD8+ T cells upon re-stimulation com-
pared with WT cDC1s (Fig. 3e & f and Additional file 1:
Figure S3b). These results indicate that TCL-loaded
cDC1s are cross-presenting the ex vivo acquired tumor
Ag to induce CD8+ T cell responses from the endogen-
ous repertoire in vivo.
Vaccination with TCL-loaded cDC1s protects against
melanoma engraftment
Next, we investigated whether the TCL-loaded cDC1-in-
duced tumor Ag-specific CD8+ T cell response would
prevent a subsequent tumor challenge. To this end, we ID
injected naive mice with B16-OVA TCL-loaded cDC1s,
followed by a boost vaccination 5 days later and ID graft-
ing of B16-OVA melanoma cells 30 days after vaccination
(Fig. 4a). cDC1-vaccinated mice showed a marked reduc-
tion of tumor growth and improved survival compared
with control mice (Fig. 4b & c). These data show that ID
administration of TCL-loaded cDC1s induces long-lasting
anti-tumor effects.
Transfer of TCL-loaded cDC1s enhances tumor-Ag-specific
T-cell presence in tumors and controls established cancer
progression
In a subsequent approach, we aimed to analyze the effi-
cacy of a cDC1-induced anti-cancer effector T cell re-
sponse in a therapeutic cancer setting. To this end, we
determined the potential of TCL-loaded cDC1s to limit
progression of established orthotopic (ID) B16-OVA
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Fig. 3 cDC1s cross-present tumor Ag to activate endogenous CD8+ T cells. a Schematic representation of experimental setup for data shown in
(b-f). PBS control or 5 × 105 poly I:C and B16-OVA TCL-loaded cDC1s were intradermally (ID) injected into mice and the draining inguinal lymph
node (iLN) analyzed 7 days thereafter. b Representative plots and c (left panel) quantification by flow cytometry of total cell number and c (right
panel) CD8+ CD44+ H-2Kb-SIINFEKL+ T cell number in iLN of mice ID injected with control PBS or 5 × 105 poly I:C and B16-OVA TCL-loaded
cDC1s. Combined data of 3 independent experiments with total n = 12 (Control) and n = 13 (cDC1s) mice are shown. ***P < 0.001 by Student’s t
test. d-f Flow cytometric quantification of d total cell number and e CD8+ CD44+ IFNγ-producing cell number after re-stimulation with OVA257–264
peptide in iLN as well as f representative plots of mice ID injected with control PBS, 5 × 105 poly I:C and B16-OVA TCL-loaded wildtype
(WT) or H-2Kbm1-harboring (H-2Kbm1) cDC1s. Combined data of 3 independent experiments with total n = 17 (Control), n = 16 (WT cDC1s) and
n = 19 (H-2Kbm1 cDC1s) mice are shown. *P < 0.05, **P < 0.01, ***P < 0.001 by one-way ANOVA and Tukey post hoc test
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injection of B16-OVA TCL-loaded cDC1s halted tumor
progression (Fig. 5b) and extended survival of tumor-
bearing mice to > 30% enhanced median survival com-
pared with control mice (Fig. 5c & d). The timing of the
melanoma growth control suggested the generation of
an anti-cancer effector T cell response, therefore we ana-
lyzed CD8+ and CD4+ T cells present in the tumor-
draining iLN (tdLN) (Fig. 5e-j and Additional file 1:
Figure S4) and the grafted B16-OVA tumor (Fig. 5k-n
and Additional file 1: Figure S5) 3 days after cDC1 admin-
istration (Fig. 5a). Indeed, tumor-bearing mice treated
with cDC1s exhibited larger tdLNs, and the number and
frequency of PD-1-expressing CD44+ activated CD8+ and
CD4+ T cells and H-2Kb- OVA257–264+ CD44+ CD8+
OVA-specific T cells was significantly enhanced in the
tdLNs, while CD44+ OVA-specific CD4+ T cells remained
unaltered (Fig. 5e & h and Additional file 1: Figure S4a-c,
f-h, k & l). Notably, re-stimulation with OVA257–264 pep-
tide, MHC class II OVA323–339 peptide-loaded APCs and/
or B16-OVA TCL-loaded APCs of CD8+ and CD4+ T
cells in tdLNs 3 days after TCL-loaded cDC1 injection re-
sulted in strongly augmented IFNγ production (Fig. 5f, g, i
& j and Additional file 1: Figure S4d, e, i & j).
We next determined T cell presence in the tumor 3
days after cDC1 treatment. At this time point, tumor
size and frequency of total or PD-1-expressing CD8+
and CD4+ T cells, as well as OVA-specific CD4+ T cells
in the tumor was equal (Additional file 1: Figure S5a-c &
e-g). In contrast, the frequency of tumor Ag-specific
H-2Kb- OVA257–264+ CD8+ T cells was strongly in-
creased after TCL-loaded cDC1 treatment (Additional
file 1: Figure S5d). Moreover, a significantly enhanced
frequency of CD8+ and CD4+ T cells producing IFNγ
upon re-stimulation with OVA257–264 peptide, OVA323–
339 peptide-loaded APCs and/or B16-OVA TCL-loaded
APCs were detected in tumors of cDC1 vaccinated mice
(Fig. 5k-n). Our results establish the efficacy of ID-ad-
ministered natural cDC1s loaded with syngeneic cell
death-induced TCL for therapeutic treatment of estab-
lished orthotopic melanoma. Mechanistically, adminis-
tration of cDC1s increases tumor Ag-specific effector
CD8+ T cells and recall responses of CD8+ and CD4+ T
cells in the tdLN and the tumor short before the de-
crease in tumor growth becomes significant.
Treatment with TCL-loaded cDC1 strongly improves anti-PD-1
therapy
In order to put the treatment with TCL-loaded natural
cDC1s into the context of current therapies, we compared
and combined it with immune checkpoint inhibition.
MC38 colon adenocarcinoma, a wildtype tumor model
that does not express any exogenous or dominant Ags,
was chosen as a tumor partially susceptible to anti-PD-1
therapy when grafted subcutaneously [28]. UV irradiation
of MC38 cancer cells induced HMGB1 release (Additional



























































Fig. 4 Vaccination with TCL-loaded cDC1s protects against melanoma engraftment. a Schematic representation of treatment and analysis. PBS
control or 0.5 × 106 poly I:C and autologous B16-OVA TCL-loaded cDC1s were intradermally (ID) injected 35 and 30 days prior to ID injection of
106 B16-OVA cancer cells (day 0) and tumor growth and survival monitored. b Tumor growth and c survival curve of mice treated as described in
(a). Combined data of 2 independent experiments with total n = 14 (Control) and n = 13 (cDC1s) mice are shown. ***P < 0.001 by b Two-way
ANOVA or c Mantel-Cox test
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UV irradiation-generated MC38 TCL resulted in upregu-
lation of CD86 and MHC-II, however not further increas-
ing poly I:C-mediated cDC1 activation (Additional file 1:
Figure S6b & c). MC38 tumor-bearing mice were treated
with cDC1s loaded with MC38 TCL when tumors were
visible (day 6) and 1 week later (day 13). Further, mice re-
ceived intraperitoneal (IP) injections of anti-PD-1 anti-




































































































































































































































































































































































































































Fig. 5 Transfer of TCL-loaded cDC1s enhances tumor-Ag-reactive T-cell presence in tumors and control established cancer progression. a Schematic
representation of treatment and analysis for data shown in (b-n). Mice were intradermally (ID) injected with 106 B16-OVA cancer cells followed by ID
injection of PBS control or 106 poly I:C and B16-OVA TCL-loaded cDC1s 5 days after, when tumors reached a size >10mm2 and < 55mm2 (day 0). Either
b-d tumor growth and survival were monitored or e-n animals sacrificed 3 days after cDC1 treatment for analysis of tumor and tumor-draining lymph
node (tdLN). b Tumor growth and c survival curve. Combined data of 2 independent experiments with total n = 18 (Control) and n = 17 (cDC1s) mice
are shown. *P < 0.05 by b Student’s t test on day 7 or c Mantel-Cox test. In a separate experiment, d tumors (n = 4) were dissected 9 days after cDC1
treatment and photographed. e-j Flow cytometric quantification of tdLN CD8+ T cells: e CD8+ CD44+ PD-1+, CD3+ CD8+ IFNγ+ or CD3+ CD4- IFNγ+
T cell number after re-stimulation with f OVA257–264 peptide or g B16-OVA TCL-loaded antigen-presenting cells (APCs) and tdLN CD4+ T cells: h CD4+
CD44+ PD-1+, CD3+ CD4+ IFNγ+ T cell number after re-stimulation with i OVA323–339 peptide-loaded APCs or j B16-OVA TCL-loaded APCs. k-n Flow
cytometric quantification and representative histogram (gated on CD3+ and CD8+, CD4- or CD4+ cells) of tumor CD8+ T cells: CD3+ CD8+ IFNγ+ or
CD3+ CD4- IFNγ+ T cell number after re-stimulation with k OVA257–264 peptide or l B16-OVA TCL-loaded APCs and tumor CD4+ T cells: CD3+ CD4+
IFNγ+ T cell number after re-stimulation with m OVA323–339 peptide-loaded APCs or n B16-OVA TCL-loaded APCs. Combined data of 2 independent
experiments with total n = 12–17 (Control) and n = 11–15 (cDC1s) mice are shown. *P < 0.05, **P < 0.01, ***P < 0.001 by Student’s t test
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cDC1 administration was overall equally efficient as
anti-PD-1 therapy in decreasing MC38 tumor progression
and extending survival of mice before reaching the hu-
mane endpoint compared with control PBS treatment
(Fig. 6b-e and Additional file 1: Figure S6d). Interestingly,
cDC1-treated mice showed a faster therapeutic effect
(Fig. 6c & d), despite almost equal timing of treatment
start and more frequent administration of anti-PD-1 anti-
body (Fig. 6a). Notably, combined treatment of MC38
tumor-bearing mice with TCL-loaded cDC1s and
anti-PD-1 was more effective than single treatments,
with complete tumor rejection in 8/18 mice (Fig. 6b-e
and Additional file 1: Figure S6d). These results sup-
port that adoptive immunotherapy with TCL-loaded
natural cDC1s improves anti-PD-1 treatment, signifi-
cantly extending survival and doubling the number of
mice cured from grafted tumors.
Immunotherapy with TCL-loaded cDC1s extends survival
of anti-PD-1-refractory B16/F10 melanoma-bearing mice
We next tested therapeutic efficacy of cDC1 administra-
tion in established ID engrafted B16/F10 melanoma, a
very aggressive tumor that does not express exogenous
or dominant Ags and is largely refractory to anti-PD-1
therapy [28, 43]. UV irradiation also induced ICD of
B16/F10 melanoma cells, as indicated by HMGB1 release
and upregulation of MHC-II and CD86, which remained
higher even upon poly I:C addition, on cDC1s exposed to
B16/F10 TCL (Additional file 1: Figure S6e-g). Natural
cDC1s loaded with syngeneic B16/F10 TCL were ID
injected 6 and 13 days after grafting of B16/F10-melano-
mas onto recipient mice, when tumors were clearly visible.
Anti-PD-1 antibody was IP injected on day 7, 10, 14 and
17 (Fig. 7a) and cancer progression monitored. As ex-
pected, mono-therapy with anti-PD-1 antibody did not
significantly alter B16/F10 tumor growth or survival as
compared with control PBS administration (Fig. 7b & c).
Notably, treatment with B16/F10 TCL-loaded cDC1s re-
duced progression of established B16/F10 melanomas as
compared with control mice, while combined admin-
istration of anti-PD-1 and TCL-loaded cDC1s mir-
rored the efficacy of cDC1 mono-treatment (Fig. 7d
& e). These results suggest that anti-PD-1-refractory
cancers could benefit from immunotherapy with ICD-
induced TCL-loaded natural cDC1s.
Discussion
The superior ability of mouse cDC1s to transport
tumor-Ag to LNs, cross-present cancer cell-associated
Ags and mediate infiltration of T cells in the tumor is
Control cDC1s+ PD-1cDC1sPD-1
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Fig. 6 Whole tumor Ag-loaded natural cDC1s reduce progression of anti-PD-1 susceptible MC38 tumors, potentiating anti-PD-1 therapy. a Schematic
representation of treatment and analysis. Mice grafted subcutaneously with 106 MC38 cancer cells (day 0) were intradermally injected with PBS (Control
and αPD-1-treated groups) or 106 poly I:C and autologous MC38 TCL-loaded cDC1s (cDC1s- and cDC1s + αPD-1-treated groups) at day 6 & 13 days as well
as intraperitoneally injected with PBS (Control and cDC1s-treated groups) or 100 μg anti-PD-1 antibody (αPD-1- and cDC1s + αPD-1-treated groups) on
days 7, 10, 14 & 17 and tumor progression monitored. b Representative images of tumors on day 20, c tumor growth, d detailed statistics of tumor size at
individual days and e survival curve before reaching the humane endpoint of mice treated as described in (a). Remaining, surviving mice in (e) completely
rejected the tumor and were followed for at least 3months. White dashed lines in (b) indicate tumor margin. Combined data of 2 independent
experiments with total n = 18 (Control, αPD-1 and cDC1s + αPD-1-treated groups) and n = 19 (cDC1s-treated group) mice are shown.
*P < 0.05, **P < 0.01, ***P < 0.001 by c Two-Way ANOVA, *P < 0.05, **P < 0.01, ***P < 0.001 by d Student’s t test, *P < 0.05, ***P < 0.001
by e Mantel-Cox test, ns: not significant
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established [14, 22, 29–31]. However, the efficiency of
adoptive transfer of syngeneic natural circulating
cDC1s for immunotherapy of cancer has not been
previously tested. This study reveals the efficacy and
feasibility of cancer-Ag loaded naturally occurring
mouse cDC1s for treatment of cancer. This next-gen-
eration DC vaccine employs: (A) the conventional
cDC1 subset purified from tumor-bearing mice that
excels in cross priming and elicits the strongest anti-
cancer CD8+ T cell responses [22, 44]; (B) the use of
poly I:C as an adjuvant that targets cDC1s via TLR3
and induces immunogenic activation, equivalent to
adjuvants currently tested for clinical use [27]
(ClinicalTrials.gov identifier: NCT02828098); (C) cDC1-
loading with a total tumor Ag preparation based on UV
irradiation-induced ICD of cancer cells, a method re-
ported to exhibit superior immunogenic potential [35, 37,
45, 46], releasing HMGB1 and activating cDC1s upon ex-
posure; (D) a convenient route of administration; and (E)
a time-efficient, economic and easy-to-use preparation
protocol with translational potential.
FLT3L-mediated expansion of DCs facilitated isolation
of mouse CD8+ cDC1s from the spleen of tumor-bear-
ing mice. Amplification of DCs by administration of
FLT3L in cancer patients is well-tolerated and might





































































































Fig. 7 Cell death-induced tumor Ag-loaded cDC1s are effective for treatment of largely anti-PD-1 refractory B16/F10 melanoma. a Schematic
representation of treatment and analysis. Mice grafted intradermally (ID) with 5 × 105 B16/F10 cancer cells (day 0) were ID injected with
PBS control (Control and αPD-1-treated groups) or 106 poly I:C and autologous B16/F10 TCL-loaded cDC1s (cDC1s- and cDC1s + αPD-1-treated
groups) at day 6 & 13 as well as intraperitoneally injected with PBS control (Control and cDC1s-treated groups) or 100 μg anti-PD-1 antibody (αPD-1-
and cDC1s + αPD-1-treated groups) at day 7, 10, 14 & 17 and tumor growth and survival monitored. b & d Tumor growth and c & e survival curve of
mice treated as described in (a). The same control group (black) is presented in (b & d) as well as in (c & e), because data belong to the same
experiment and are split for clarity. The graphs are displayed separately for better visibility. Combined data of 2 independent experiments
with total n = 16 (Control, αPD-1 and cDC1s + αPD-1-treated groups) and n = 17 (cDC1s-treated group) mice are shown. *P < 0.05 by b &
d Student’s t test at day 12 and 13 and **P < 0.01 by c & e Mantel-Cox test, ns: not significant
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itself in humans and mice [9, 29, 47]. Separation of nat-
ural CD1c + cDCs (cDC2s) and BDCA4+ pDCs from hu-
man leukapheresis products without the need for
fluorescence-activated cell sorting and in good manufac-
turing practice (GMP) conditions was already achieved
[16, 17] and technological advances will hopefully soon
make GMP isolation of human BDCA3+ cDC1s possible
(PROCROP Cancer Immunotherapy European Initia-
tive Web Site. http://www.procrop.eu (2015); accessed
25 Feb 2019).
Herein, we establish the proof of principle that mouse
natural cDC1s treated ex vivo with adjuvant and
tumor-Ag for a very short time are efficient to induce
Ag-specific anti-cancer CD8+ and CD4+ T cell re-
sponses in vivo. UV irradiation followed by secondary
necrosis and generation of TCL from three different
cancer cell lines served as source of immunogenic tumor
cell Ag for cDC1s. Loading of cDC1s with cell death-in-
duced TCL caused much more effective induction of
CD8+ T cell activation than loading cDC1s with soluble
protein. This result highlights that UV irradiation-in-
duced TCL not only contains a plethora of tumor
cell-associated Ags, but also danger signals like HMGB1
that activate cDC1s and their capacity for tumor Ag pro-
cessing [35, 37, 40, 41, 45, 46]. Indeed, some cytostatic
agents, such as anthracyclines and UV irradiation, in-
duce ICD associated with a spatiotemporal release of
danger-associated molecular patterns (such as calreticu-
lin, ATP, HMGB1 and F-actin). Thereby, in contrast to
apoptosis that has rather tolerogenic effects, ICD acts as
potent stimulator of adaptive immunity, which depends
on the presence of DCs [37–41, 45]. RIPK1 signaling
and NF-κB-induced transcription in dying tumor cells
also increase cross-priming efficiency and anti-tumor
immunity [48]. Cell-associated danger signals associated
with ICD like calreticulin promote phagocytosis, while
adjuvants such as HMGB1 or F-actin induce DC acti-
vation, tumor Ag processing and cross-presentation
[40, 41, 45, 49]. This is consistent with our results
showing that UV irradiation causes HMGB1 release
from three different mouse cancer cells lines and sol-
uble factors in the resulting TCL induce DC activa-
tion. Moreover, treatment of natural cDC1s with both
poly I:C adjuvant and TCL derived from UV-dead
cells is needed for optimal CD8+ T cell
cross-priming. Accordingly, a recent study showed that
the combination of poly I:C activation and provision of
necrotic cell-associated material caused human BDCA3+
cDC1s to outperform CD1c+ cDC2 and moDC subsets in
Ag uptake, internalization and cross-presentation [50].
The here reported next-generation cDC1-based anti-
cancer vaccine strongly induced anti-cancer effector
CD8+ T cell responses from the endogenous repertoire
in the skin-draining LN. Those responses appear to
largely depend on the MHC class I-mediated presenta-
tion of the Ag loaded ex vivo onto cDC1s, because
H-2Kbm1 cDC1s, which fail to efficiently present
OVA257–264 peptide on MHC-I [42], were significantly
less potent than WT cDC1s. Notwithstanding, vaccination
with H-2Kbm1-harboring cDC1s induced some degree of
specific CD8+ T cell response, suggesting that cDC1s may
also transfer ex vivo obtained Ag to endogenous Ag pre-
senting cells upon injection in vivo, consistent with a role
of cDC1s in tumor Ag transport to tdLNs [29, 30].
CD8+ and CD4+ T cell activation induced by adminis-
tration of TCL-loaded cDC1s contributes to reduced
tumor progression and even remission of established tu-
mors derived from the three cancer cell lines B16-OVA,
B16/F10 and MC38, the latter two not expressing
exogenous Ags. The effector tumor Ag-specific and
cancer-reactive CD8+ and CD4+ T cell response from
the endogenous repertoire is enhanced both in the
tumor and tdLN and precedes delays in tumor growth.
Moreover, our next-generation cDC1 anti-cancer vac-
cine was also effective in a preventive cancer setting,
suggesting induction of enduring immune responses and
probably the formation of immune memory, which
would indicate a potential efficacy preventing metastasis.
Moreover, cDC1s were shown to contribute to optimal
generation of tissue-resident memory CD8+ T cells [51],
a memory subset that promotes anti-tumor immunity in
concert with circulating memory CD8+ T cells [52]. This
observation may have implications for adjuvant vaccin-
ation in postsurgical minimal residual disease settings.
Anti-PD-1 therapy is the current standard treatment
for many cancer types [3, 4]. Efficacy of therapy with
PD-1 blockade in mouse cancer models is dependent on
cDC1s [28, 29]. In addition, we observe that administra-
tion of TCL-loaded cDC1s increased PD-1+ CD8+ and
CD4+ T cell numbers in tdLNs. Therefore, it was im-
portant to compare and combine our next-generation
cDC1 anti-cancer vaccine with anti-PD-1 blockade.
Tumor Ag-loaded cDC1 mono-therapy was equally suc-
cessful as anti-PD-1 treatment in grafted MC38 tumors.
Notably, cDC1 administration was immediately effective,
suggesting that it enlarges the pool of anti-cancer T cells
which could explain the synergism of combination ther-
apy with anti-PD-1 blockade in this model. Administra-
tion of TCL-loaded cDC1 is also effective in B16/F10
tumors, which are anti-PD-1-refractory [28]. This result
supports the notion that DC-based cancer immunother-
apy can act in synergy and go beyond checkpoint anti-
body therapy, which is crucial to improve treatment for
tumors resistant to current strategies [4, 8, 22].
We have established the proof of principle showing
that adoptive transfer of TCL-loaded and adjuvant-acti-
vated cDC1s is effective in cancer immunotherapy.
However, we intentionally did not compare this therapy
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with administration of other DC subsets in the mouse
system. Apart from the only clinically approved
Sipuleucel-T treatment [7], there is currently no gold
standard for DC therapy regarding DC subset, incuba-
tion time, Ag and/or adjuvant that would serve for com-
parison in humans [10], and less so in mice. Moreover,
while cDC1s specialize on cross-presentation of cell-as-
sociated Ags in the mouse, the unique functions of the
human cDC1 equivalents are also debated [15, 18–22].
Notably, analysis of several datasets including The Cancer
Genome Atlas (TCGA) suggest that a cDC1 signature
within many human tumors is associated with improved
survival [26, 30, 32, 33]. Nonetheless, anti-cancer effects
of DC-based vaccines will likely depend on numerous fac-
tors, including the nature of potential Ags available for a
certain tumor type (identified neoantigens or tumor pep-
tides, etc.) and, hence, the Ag and adjuvant cocktail used
to load DCs. In addition, different tumors may benefit
from generation of distinct types of immunity: for in-
stance, a cDC2-dependent Th17 response may be benefi-
cial in certain cancer models [53].
Conclusions
Our proof-of-principle study provides, for the first time,
pre-clinical data showing suitability and efficacy of thera-
peutic cross-presenting cDC1-based vaccination. Overall,
our results suggest a feasible scenario for patient treat-
ment based on administration of tumor-Ag-loaded cDC1s.
We show efficacy of a cDC1-based therapy that does not
require identification of tumor neoantigens, representing
an easily achievable personalized Ag source for virtually
any resected tumor. Circulating cDC1s isolated from leuka-
pheresis products of patients, eventually undergoing add-
itional treatments with FLT3L to enhance cDC1 numbers,
can then be shortly exposed to autologous tumor-Ag and
adjuvant before reinfusion. This strategy would reduce
long-term cell cultures that make the process labor in-
tensive and reduce reproducibility. Our results show
the potential of this cDC1-based vaccine to be com-
bined with standard anti-PD-1 therapy [54] or used in
anti-PD-1 resistant tumors, inducing both effector
and long-lasting anti-tumor CD8+ and CD4+ T cell
responses. These prospects will be tested as soon as
GMP isolation of human natural cDC1s is feasible.
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cells in tumor-draining lymph node after administration of tumor Ag-
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tumor Ag-loaded cDC1s. Figure S6. UV irradiation-induced ICD of MC38
and B16/F10 cancer cells results in HMGB1 release and cDC1 activation.
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